References
- Chavda VP, Apostolopoulos V. Mosaic receptor binding domain nanoparticles: towards fourth-generation vaccination. Nanomed [Internet]. 2023 Oct 28;18(19):1223–1226. doi: 10.2217/nnm-2022-0316
- Chavda VP, Bezbaruah R, Athalye M, et al. Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena. Viruses. 2022;14(4):14. doi: 10.3390/v14040759
- Chavda VP, Sonak SS, Munshi NK, et al. Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int. 2022;29(42):62887–62912. doi: 10.1007/s11356-022-21967-4
- Wilder-Smith A, Osman S. Public health emergencies of international concern: a historic overview. J Travel Med [Internet]. 2020 [cited 2023 Dec 10];27:taaa227. doi: 10.1093/jtm/taaa227
- Chavda VP, Ghali ENHK, Balar PC, et al. Protein subunit vaccines: promising frontiers against COVID-19. J Controlled Release [Internet]. 2024;366:761–782. https://www.sciencedirect.com/science/article/pii/S016836592400021X
- Sachs JD, Karim SSA, Aknin L, et al. The lancet commission on lessons for the future from the COVID-19 pandemic. Lancet [Internet]. 2022 [cited 2023 Dec 9];400:1224–1280. doi: 10.1016/S0140-6736(22)01585-9
- Chavda VP, Apostolopoulos V. COVID-19 vaccine design and vaccination strategy for emerging variants. Expert Rev Vaccines [Internet]. 2022;21:1359–1361. doi: 10.1080/14760584.2022.2112571
- Labib SM, Browning MHEM, Rigolon A, et al. Nature’s contributions in coping with a pandemic in the 21st century: a narrative review of evidence during COVID-19. Sci Total Environ [Internet]. 2022;833:155095. Available from: https://www.sciencedirect.com/science/article/pii/S004896972202188X
- Chavda VP, Yao Q, Vora LK, et al. Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world. Front Immunol [Internet]. 2022;13. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.961198
- Chavda VP, Bezbaruah R, Deka K, et al. The Delta and omicron variants of SARS-CoV-2: what we know so far. Vaccines. 2022;10(11):10. doi: 10.3390/vaccines10111926
- Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol [Internet]. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7
- Bayarri-Olmos R, Johnsen LB, Idorn M, et al. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. In: Sato K, Davenport MP, editors. eLife [Internet]. 2021;10:e70002. doi: 10.7554/eLife.70002
- Tao K, Tzou PL, Nouhin J, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet [Internet]. 2021;22(12):757–773. doi: 10.1038/s41576-021-00408-x
- Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines [Internet]. 2022;21:597–600. doi: 10.1080/14760584.2022.2044800
- Shiehzadegan S, Alaghemand N, Fox M, et al. Analysis of the delta variant B.1.617.2 COVID-19. Clin Pract [Internet]. 2021;11(4):778–784. Available from: https://pubmed.ncbi.nlm.nih.gov/34698149
- Saberiyan M, Karimi E, Khademi Z, et al. SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cell Mol Biol Lett [Internet]. 2022;27(1):50. doi: 10.1186/s11658-022-00352-6
- Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med [Internet]. 2022;386(16):1532–1546. doi: 10.1056/NEJMoa2119451
- Pather S, Madhi SA, Cowling BJ, et al. Corrigendum: SARS-CoV-2 omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front Immunol [Internet]. 2023;14. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1130539
- Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and immunogenicity of the third Booster Dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines. 2022;10(1):86–86. doi: 10.3390/vaccines10010086
- Guyot G, Sayah S, Guernouti S, et al. Role of ventilation on the transmission of viruses in buildings, from a single zone to a multizone approach. Indoor Air [Internet]. 2022 cited 2023 Dec 10;32(8):e13097. doi: 10.1111/ina.13097
- Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol [Internet]. 2023;21(6):361–379. doi: 10.1038/s41579-023-00878-2
- Mina MJ, Parker R, Larremore DB. Rethinking covid-19 test sensitivity — a strategy for containment. N Engl J Med [Internet]. 2020 [cited 2023 Dec 10];383(22):e120. doi: 10.1056/NEJMp2025631
- Filchakova O, Dossym D, Ilyas A, et al. Review of COVID-19 testing and diagnostic methods. Talanta [Internet]. 2022;244:123409. Available from: https://www.sciencedirect.com/science/article/pii/S0039914022002053
- Soroka M, Wasowicz B, Rymaszewska A. Loop-mediated isothermal amplification (LAMP): the better sibling of PCR? Cells. 2021;10(8):10. doi: 10.3390/cells10081931
- Huang L, Wang D, Chen H, et al. CRISPR-detector: fast and accurate detection, visualization, and annotation of genome-wide mutations induced by genome editing events. J Genet Genomics [Internet]. 2023;50(8):563–572. Available from: https://www.sciencedirect.com/science/article/pii/S1673852723000747
- Fernandes RS, de Oliveira Silva J, Gomes KB, et al. Recent advances in point of care testing for COVID-19 detection. Biomed Pharmacother [Internet]. 2022;153:113538. Available from: https://www.sciencedirect.com/science/article/pii/S0753332222009271
- Budd J, Miller BS, Weckman NE, et al. Lateral flow test engineering and lessons learned from COVID-19. Nat Rev Bioeng [Internet]. 2023;1(1):13–31. doi: 10.1038/s44222-022-00007-3
- Satam H, Joshi K, Mangrolia U, et al. Next-generation sequencing technology: current trends and advancements. Biology. 2023;12(7):12. doi: 10.3390/biology12070997
- Lino C, Barrias S, Chaves R, et al. Biosensors as diagnostic tools in clinical applications. Biochim Biophys Acta BBA - Rev Cancer [Internet]. 2022;1877(3):188726. Available from: https://www.sciencedirect.com/science/article/pii/S0304419X22000518
- Dinnes J, Sharma P, Berhane S, et al. Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database Syst Rev. 2022;2022(7). doi: 10.1002/14651858.CD013705.pub3
- Lagziel T, Quiroga L, Ramos M, et al. Two false negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and suspected stevens-johnson syndrome/Toxic epidermal necrolysis (SJS/TEN). Cureus [Internet]. 2020;12:e8198. doi: 10.7759/cureus.8198
- Lai KW, Chang CY, Loo WK, et al. Chapter 12 - classification of COVID-19 and non-COVID-19 lung computed tomography images using machine learning. In: Rajput S, Khan N Singh A, editors. Digit Image Enhanc Reconstr [Internet]. Academic Press; 2023. p. 269–292. Available from: https://www.sciencedirect.com/science/article/pii/B9780323983709000196
- Lasrado N, Collier AY, Hachmann NP, et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine [Internet]. 2023;41(47):6904–6909. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X23012537
- Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Rev Vaccines [Internet]. 2021;20:635–638. doi: 10.1080/14760584.2021.1915140
- Selvavinayagam ST, Karishma SJ, Hemashree K, et al. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India – a cohort study. Lancet Reg Health - Southeast Asia [Internet]. 2023 Dec 10;19:100272. doi: 10.1016/j.lansea.2023.100272
- Abbasi J. What to know about EG.5, the latest SARS-CoV-2 “variant of interest”. JAMA. 2023 Dec 11;330(10):900–901. doi: 10.1001/jama.2023.16498
- Tanriover MD, Akova M. COVID-19 vaccine booster strategy: striving for best practice. Lancet Glob Health [Internet]. 2022 [cited 2023 Dec 10];10:e774–e775. doi: 10.1016/S2214-109X(22)00204-2
- Kelly SL, Le Rutte EA, Richter M, et al. COVID-19 vaccine booster strategies in light of emerging viral variants: frequency, timing, and target groups. Infect Dis Ther [Internet]. 2022;11(5):2045–2061. doi: 10.1007/s40121-022-00683-z
- Tan M, Straughan PT, Cheong G. Information trust and COVID-19 vaccine hesitancy amongst middle-aged and older adults in Singapore: a latent class analysis approach. Soc Sci Med [Internet]. 2022;296:114767. Available from: https://www.sciencedirect.com/science/article/pii/S0277953622000703
- Lazarus JV, Wyka K, White TM, et al. A survey of COVID-19 vaccine acceptance across 23 countries in 2022. Nat Med [Internet]. 2023;29(2):366–375. doi: 10.1038/s41591-022-02185-4
- Kim S, Willis E, Wehlage S, et al. COVID-19 vaccine hesitancy and short-term and long-term intentions among unvaccinated young adults: a mixed-method approach. BMC Public Health [Internet]. 2022;22(1):2030. doi: 10.1186/s12889-022-14448-3
- Frisch M, Chaudhary W, Zhang X, et al. Addressing COVID-19 vaccine hesitancy: the role of medical students. Med Sci Educ [Internet]. 2022;32:1299–1303. doi: 10.1007/s40670-022-01670-2
- Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine [internet]. 2024; Available from: https://www.sciencedirect.com/science/article/pii/S0264410X24001270
- Li G, Hilgenfeld R, Whitley R, et al. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov [Internet]. 2023;22(6):449–475. doi: 10.1038/s41573-023-00672-y
- Chavda VP, Prajapati R, Lathigara D, et al. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther [Internet]. 2022;22:763–780. doi: 10.1080/14712598.2022.2078160
- Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr res pharmacol drug discov [internet]. 2022; p. 100086–100086. Available from: https://www.sciencedirect.com/science/article/pii/S2590257122000062
- Hossain MK, Hassanzadeganroudsari M, Feehan J, et al. COVID-19 vaccines in the pipeline, are antibodies adequate? Vaccines. 2021;9(3):241. doi: 10.3390/vaccines9030241
- Teli D, Balar P, Patel K, et al. Molnupiravir: a versatile prodrug against SARS-CoV-2 variants. Metabolites. 2023;13(2):309. doi: 10.3390/metabo13020309
- Ridgway H, Orbell JD, Matsoukas M-T, et al. W254 in furin functions as a molecular gate promoting anti-viral drug binding: elucidation of putative drug tunneling and docking by non-equilibrium molecular dynamics. Comput Struct Biotechnol J [Internet]. 2023 [cited 2024 Feb 13];21:4589–4612. doi: 10.1016/j.csbj.2023.09.003
- Swiderski J, Gadanec LK, Apostolopoulos V, et al. Role of angiotensin II in cardiovascular diseases: introducing bisartans as a novel therapy for coronavirus 2019. Biomolecules. 2023;13(5):787. doi: 10.3390/biom13050787
- Ridgway H, Ntallis C, Chasapis CT, et al. Molecular epidemiology of SARS-CoV-2: the dominant role of arginine in mutations and infectivity. Viruses. 2023;15(2):15. doi: 10.3390/v15020309
- Apostolopoulos V, Bojarska J, Feehan J, et al. Smart therapies against global pandemics: a potential of short peptides. Front Pharmacol [Internet]. 2022;13. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.914467
- Hossain MK, Hassanzadeganroudsari M, Feehan J, et al. The race for a COVID-19 vaccine: where are we up to? Expert Rev Vaccines. 2022;21(3):355–376. doi: 10.1080/14760584.2022.2021074
- Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther [Internet]. 2022;20:17–21. doi: 10.1080/14787210.2021.1939683
- Kelleni MT. Evolution of SARS CoV-2 Omicron subvariants BF.7 and XBB.1.5: time to follow Africa and abort all COVID restrictions. J Infect [Internet]. 2023 [cited 2024 Mar 28];86:405. doi: 10.1016/j.jinf.2023.01.027
- Cai X, Fry CV, Wagner CS. International collaboration during the COVID-19 crisis: autumn 2020 developments. Scientometrics [Internet]. 2021;126(4):3683–3692. doi: 10.1007/s11192-021-03873-7
- Hameed M, Najafi M, Cheeti S, et al. Factors influencing international collaboration on the prevention of COVID-19. Public Health [Internet]. 2022;212:95–101. Available from: https://www.sciencedirect.com/science/article/pii/S0033350622002530
- Jiang D, Wang X, Zhao R. Analysis on the economic recovery in the Post-COVID-19 era: evidence from China. Front Public Health [Internet]. 2022;9. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2021.787190
- Okafor L, Khalid U, Gopalan S. COVID-19 economic policy response, resilience and tourism recovery. Ann Tour Res Empir Insights [Internet]. 2022;3(2):100073. Available from: https://www.sciencedirect.com/science/article/pii/S2666957922000416
- Aditya B, Amri I. Rethinking informal economy resilience during crisis: experience from COVID-19 pandemic. Ind J Labour Econ. 2023;66(3):711–737. doi: 10.1007/s41027-023-00458-1
- Brada JC, Gajewski P, Kutan AM. Economic resiliency and recovery, lessons from the financial crisis for the COVID-19 pandemic: a regional perspective from central and Eastern Europe. Int Rev Financ Anal [Internet]. 2021;74:101658. Available from: https://www.sciencedirect.com/science/article/pii/S1057521921000028